We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Celgene has announced results from an open-label phase II/III study led by the ECOG-ACRIN Cancer Research Group and sponsored by the National Cancer Institute (NCI).